Archives: 2022-02-16

PIER MARIA FORNASARI
2022-02-16

Virome characterization of wild mammalian game animals, traded and consumed as exotic food in China, reveals a spectrum of emerging pathogens

This study has greatly expanded the understanding of the diversity of viruses carried by a variety of wild animals, and provided an important scientific basis for the early warning and prevention of human and livestock diseases.Vertebrate-associated viruses carried in wildlife The world’s top academic journal Cell published a research paper online: “Virome characterization of game

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-02-15

U.S. peer-reviewed study on Omicron patient outcomes reveals significant differences in infection behavior

Within only three weeks after the Omicron variant was first identified among Houston Methodist patients, this variant rapidly took over and became the cause of a majority of new cases. By contrast, the delta variant took about three months to reach that same milestone after initial detection. Causing 98 percent of all new COVID-19 cases

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-02-15

Using stem cells to regenerate the heart: identified key molecule for recognizing epicardial cells, the source of many cell types in a growing heart.

Heart disease remains the leading cause of death in the world. One reason is that unlike other tissues, such as bone and skin, the heart has remarkably poor regenerative capability after an injury such as a heart attack. Scientists have therefore searched for heart cells that have regenerative properties. A new study by the Yoshinori

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2022-02-15

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott–Aldrich syndrome

Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), announced today that its lentiviral based gene therapy, developed in collaboration with French and British teams, has demonstrated long-term efficacy in eight patients with Wiskott-Aldrich syndrome, a rare and severe immune deficiency. “These results confirm the stability and good

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-02-13

COVID-19 infections increase risk of heart conditions up to a year later

Cardiovascular care essential part of post-infection care An in-depth analysis of federal health data indicates that people who have had COVID-19 are at increased risk of developing cardiovascular complications within the first month to a year after infection. Such complications include disruptive heart rhythms, inflammation of the heart, blood clots, stroke, coronary artery disease, heart

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-02-08

Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis in three patients as published in Nature Medicine

A system developed by Grégoire Courtine and Jocelyne Bloch now enables patients with a complete spinal cord injury to stand, walk and even perform recreational activities like swimming, cycling andcanoeing. The images made headlines around the world in late 2018. David Mzee, who had been left paralyzed by a partial spinal cord injury suffered in

Read More

No Comments InRESEARCH
PIER MARIA FORNASARI
2022-02-06

Gene therapy in transfusion-dependent beta-thalassemia

A novel gene therapy promoted transfusion independence in more than 90 percent of adult and pediatric patients with transfusion-dependent beta-thalassemia, according to a recent clinical trial published in The New England Journal of Medicine. The therapy represents a potentially curative treatment option for patients who must otherwise rely on life-long red blood cell transfusions. This approach provides

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2022-02-06

Study of Penn Patients with Decade-Long Leukemia Remissions after CAR T Cell Therapy Reveals New Details About Persistence of Personalized “Living Drug” Cells

Two patients represent longest-known CAR T cell response to date, providing insight into treatment effects and outcomes In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-01-26

FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19

The U.S. Food and Drug Administration took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. This provides another treatment option to reduce the risk of hospitalization in high-risk patients. Previously, the use of Veklury was limited to

Read More

No Comments InCovid-19